March 2016 Newsletter
IASLC-LCFA Joint Scholarships
The IASLC and the Lung Cancer Foundation of America (LCFA) are proud to announce a Request for Application for the LCFA/IASLC Lori Monroe Scholarship in Translational Lung Cancer Research. The scholarship will fund two lung cancer research grants over two years. Each grant recipient will receive $200,000. The objective of this award is to support research that improves the care of individuals with lung cancers and to reduce the burden of these diseases.
New IASLC Annual Report
We published and distributed our 2015 Annual Report in the middle of February. The report documents IASLC's major achievements during 2015, including the WCLC in Denver, and looks toward our promising future in 2016 and beyond.
We mailed a copy of the Annual Report to all our members and we encourage you to review the important work of our organization. Click here to read the new Annual Report online.
Please also notice the letter included with your Annual Report, as it includes important information about your membership status.
If you did not receive a copy of the Annual Report, please email email@example.com.
AACR-IASLC Abstracts Now Online
Thank you to all those who attended the Fourth AACR-IASLC International Joint Conference on Lung Cancer: Translational Science from the Bench to the Clinic in San Diego last month.
All abstracts from those who provided permission are now live as a supplement on the Journal of Thoracic Oncology's website.
The International Mentorship Award Program is a professional development and education program for early-career physicians/researchers studying thoracic malignancies from economically-developing countries. Award recipients receive registration to the IASLC 17th World Conference on Lung Cancer in Vienna, Austria from Dec. 4-7, 2016 and are matched with well-established scientific and clinical IASLC mentors from within Europe to visit the mentor’s institution for approximately a week (Dec. 9-15) following the WCLC.
Goals of the Program
The IASLC Member Directory is currently in production and will be distributed in early April. All members have been sent a communication to verify the details that will be included in the Member Directory, and to update all current contact details. If you have not seen this communication from IASLC, we ask you to please contact firstname.lastname@example.org with any information changes or preferences for the Member Directory. The membership survey also asks your preference for delivery of the IASLC Member Directory, which can be mailed to members at no charge. Or, you can opt-out of print delivery and just use the online, searchable directory.
Membership Feedback Survey
Thank you to all our members who completed the IASLC Membership Survey. We had a record response rate of over 25 percent of the membership completing the survey. As an incentive to complete the survey, IASLC again offered a drawing of all survey responders to win an iPad. We are pleased to announce this year’s winner: David Spigel, MD, Medical Oncologist and Director of Lung Cancer Research at Sarah Cannon Research Institute in Nashville, TN, USA. Dr. Spigel chose to donate the iPad back to the IASLC. The Membership Committee will review the survey results and provide a brief summary in a future newsletter. Feedback from members is always welcome and can be sent to email@example.com.
As a service to our members we post opportunities related to lung cancer and other thoracic malignancies on our website.
This now includes academic career opportunities. Click here to review post-doctoral and other career opportunities submitted to IASLC. If you have an academic career opportunity, please email it to firstname.lastname@example.org.
We also post information when we receive information from grantors. We currently have four funding opportunities posted:
These opportunities are available to applicants from all countries. Click here to learn more.
Social Media Corner: Building a Community
By Mary Hesdorffer, Nurse Practitioner
To help our members understand and better use social media, this month we are focusing on the opportunities provided through Facebook. With the proliferation of social media, the Mesothelioma Applied Research Foundation formalized its use of Facebook groups to deliver online support services.
The Meso Foundation does so by strictly following certain parameters:
Users of online support groups on Facebook report that the ease of use, 24/7 availability, and archived threads are distinct advantages. A survey of members showed that nearly half of the patient participants enrolled in clinical trials, demonstrating that patients who seek expert guidance and support from the Foundation, and especially those who stay connected through professionally moderated groups, are more apt to participate in clinical trials.
March 2016: The IASLC and the Journal of Thoracic Oncology (JTO) are pleased to present the Editor's Choice each month to highlight certain articles of interest. The selected articles each month will be made available to the public for a limited time upon printing. The articles below from the March issue of JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
The IASLC Lung Cancer Staging Committee has embarked on revisions for the 8th edition of the TNM classification for lung cancer. The first four manuscripts describing the T, N and M descriptors as well as the stage groupings were published in July, November and December 2015, as well as in January 2016. In this issue, Nicholson and colleagues provide information on the clinical and pathologic staging of small cell lung cancer.
First-line Afatinib Versus Chemotherapy in Non-Small-Cell Lung Cancer Patients with Common Epidermal Growth Factor Receptor Mutations and Brain Metastases
Schuler et al have retrospectively evaluated the potential role of afatinib in treating brain metastases in EGFR mutant positive NSCLC in their study. Dr. Ou and colleagues have written a very insightful editorial to accompany this work. (Read the press release.)
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
KRAS is the most commonly mutated oncogene in lung cancer. However, apart from major difficulties in directly inhibiting mutant KRAS, the prognostic value of KRAS mutation remains controversial. Our final selection highlights the prognostic and predictive effects of mutant KRAS in the setting of EGFR TKI therapy in NSCLC.
The following articles have been selected from the JTO by the IASLC Communications Committee to be promoted to the media and the public with press releases that were released at the time of online publication (Published Ahead of Print). To read more IASLC Press Releases, please visit IASLC Research Articles. These press releases are also announced via social media, so please follow IASLC on Twitter and Facebook to stay up to date on the latest scientific topics!
Preliminary research has identified autoantibodies, immune proteins found in the blood specific for one’s own proteins, that can potentially detect lung cancer early by distinguishing between smokers with or without lung cancer and also discriminate between lung cancer and low-dose computed tomography (LDCT) detected non-cancerous lung lesions.
Feb. 17, 2016 | More
FDA-Approved ALK IHC CDx is Superior to Another IHC Assay for
|First Name||Last Name||Country||Primary Specialty|
|Chen||Guo Han||China||Thoracic Surgery|
|Maryam||Ramezani Aghdam||Iran||Basic Sciences|
|Sergey||Gerasimov||Russian Federation||Thoracic Surgery|
|Jae Hyun||Jeon||South Korea||Thoracic Surgery|
|Emma||Bates||United Kingdom||Radiation Oncology|
|Almudena||Cascales||United Kingdom||Radiation Oncology|
|Shahul||Leyakathali Khan||United Kingdom||Pulmonary Medicine|
|Timothy||Yap||United Kingdom||Medical Oncology|
|Mark||Berry||United States||Thoracic Surgery|
|Roger||Dansey||United States||Medical Oncology|
|Dan||Edelstein||United States||Medical Oncology|
|David||Feller-Kopman||United States||Pulmonary Medicine|
|Brian||Haney||United States||Medical Oncology|
|Tomasz||Szczudlo||United States||Medical Oncology|
|David||Weissman||United States||Pulmonary Medicine|
|Margaret||Wojtowicz||United States||Medical Oncology|
Patient Advocacy Meeting During Targeted Therapies Meeting
Patient advocates from all parts of the U.S. met in Santa Monica on Feb. 19 for a meeting to discuss a proposal by IASLC CEO Fred R. Hirsch to harmonize the strategy for Lung Cancer Awareness Month in November 2016. Attendees agreed that a common strategy would benefit all lung cancer organizations and felt that IASLC should help lead this unified effort.
Attendees agreed to support a major public awareness campaign, jointly supported by all organizations, including a consensus on the key reasons for public awareness. To implement this plan, IASLC Director of Membership and Patient Advocacy Committee Liaison Kristin Richeimer will serve as project lead, facilitating a series of monthly calls beginning in March.
We welcome the participation of all patient advocacy groups, survivors and individual patient advocates. If you have not yet received information about this initiative, please contact Kristin directly.
Team Draft Check Presentation
The IASLC Foundation was honored to receive nearly US$5,000 from the Chris Draft Foundation as a result of the Team Draft Super Bowl Challenge. Lung cancer survivor and IASLC member Kathy Weber took the challenge to raise money on behalf of the IASLC Foundation and won second place. That meant Kathy and her family attended the NFL Pro Bowl in Hawaii in January.
Kathy and former NFL player Chris Draft presented the donation to IASLC CEO Dr. Fred R. Hirsch on Feb. 22 (Pictured right). The donation will help the IASLC Foundation fund fellowships for researchers around the world seeking new ways to conquer thoracic malignancies. The first place winner of the Super Bowl Challenge, Kim Ringen, attended the Super Bowl in early February. Kim is also an IASLC member.
|· JTO · Research & Education · Patient Resources · Membership ·|
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
February 20 - 23 2019Santa Monica, California
April 3 - 5 2019New York, New York
April 10 - 13 2019Geneva, Switzerland